The common cold: potential for future prevention or cure

Maria Passioti, Paraskevi Maggina, Spyridon Megremis, Nikolaos G Papadopoulos, Maria Passioti, Paraskevi Maggina, Spyridon Megremis, Nikolaos G Papadopoulos

Abstract

The common cold is the most frequent, although generally mild, human disease. Human Rhinoviruses are the prevalent causative agents, but other viruses are also implicated. Being so common, viral colds, have significant implications on public health and quality of life, but may also be life-threatening for vulnerable groups of patients. Specific diagnosis and treatment of the common cold still remain unmet needs. Molecular diagnostic techniques allow specific detection of known pathogens as well as the identification of newly emerging viruses. Although a number of medications or natural treatments have been shown to have some effect, either on the number or on the severity of common colds, no single agent is considerably effective. Virus-specific management remains in most cases a challenging potential as many factors have to be taken into account, including the diversity of the viral genomes, the heterogeneity of affected individuals, as well as the complexity of this long standing host-virus relationship.

Figures

Fig. 1
Fig. 1
Common cold symptoms and possible complications result from a dynamic interplay between infecting virus characteristics and host’s immune response. In the majority of cases, common cold is a relatively mild and self limited illness. However, affected individuals with defective immunity -either because of an underlying condition (i.e. asthma, immunodeficiency, young or old age) or as a result of environmental conditions (i.e. smoking, stress, pollution)- may experience severe (even fatal) complications.

References

    1. Fokkens WJ, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:3.
    1. Heikkinen T, Jarvinen A. The common cold. Lancet. 2003;361(9351):51–9.
    1. Roelen CA, Koopmans PC, Notenbomer A, Groothoff JW, et al. Job satisfaction and short sickness absence due to the common cold. Work. 2011;39(3):305–13.
    1. Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev. 2013;6:CD000247.
    1. Leder K, Sinclair MI, Mitakakis TZ, Hellard ME, Forbes A. A community-based study of respiratory episodes in Melbourne, Australia. Aust N Z J Public Health. 2003;27(4):399–404.
    1. Gruber C, et al. History of respiratory infections in the first 12 yr among children from a birth cohort. Pediatr Allergy Immunol. 2008;19(6):505–12.
    1. Ball TM, et al. Influence of attendance at day care on the common cold from birth through 13 years of age. Arch Pediatr Adolesc Med. 2002;156(2):121–6.
    1. Pitkaranta A, et al. Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children. J Clin Virol. 1999;14(3):199–205.
    1. Cohen S, et al. Positive emotional style predicts resistance to illness after experimental exposure to rhinovirus or influenza a virus. Psychosom Med. 2006;68(6):809–15.
    1. Herlov-Nielsen H, Permin H. Common cold–risk factors, transmission and treatment. Ugeskr Laeger. 2001;163(41):5643–6.
    1. Nieman DC. Exercise, upper respiratory tract infection, and the immune system. Med Sci Sports Exerc. 1994;26(2):128–39.
    1. Makela MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36(2):539–42.
    1. Monto AS. Epidemiology of viral respiratory infections. Am J Med. 2002;112(Suppl 6A):4S–12S.
    1. Grief SN. Upper respiratory infections. Prim Care. 2013;40(3):757–70.
    1. Jartti T, Jartti L, Ruuskanen O, Söderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med. 2012;18(3):271–8.
    1. Weigl JA, et al. Ten years' experience with year-round active surveillance of up to 19 respiratory pathogens in children. Eur J Pediatr. 2007;166(9):957–66.
    1. Kahn J. Human bocavirus: clinical significance and implications. Curr Opin Pediatr. 2008;20(1):62–6.
    1. Gwaltney JM, Jr, et al. Rhinovirus infections in an industrial population. I. The occurrence of illness. N Engl J Med. 1966;275(23):1261–8.
    1. Monto AS, Johnson KM. A community study of respiratory infections in the tropics. II. The spread of six rhinovirus isolates within the community. Am J Epidemiol. 1968;88(1):55–68.
    1. Briese T, et al. Global distribution of novel rhinovirus genotype. Emerg Infect Dis. 2008;14(6):944–7.
    1. Arakawa M, Okamoto-Nakagawa R, Toda S, Tsukagoshi H, Kobayashi M, Ryo A. Molecular epidemiological study of human rhinovirus species A, B and C from patients with acute respiratory illnesses in Japan. J Med Microbiol. 2012;61(3):410–9.
    1. Jefferson T, Del Mar C, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2011;7:CD006207.
    1. Gern JE, et al. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med. 2000;162(6):2226–31.
    1. Jacobs SE, et al. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135–62.
    1. Winther B, et al. Light and scanning electron microscopy of nasal biopsy material from patients with naturally acquired common colds. Acta Otolaryngol. 1984;97(3–4):309–18.
    1. Triantafilou K, Vakakis E, Richer EA, Evans GL, Villiers JP, Triantafilou M. Human rhinovirus recognition in non-immune cells is mediated by Toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response. Virulence. 2011;2(1):22–9.
    1. Papadopoulos NG, et al. Rhinoviruses infect the lower airways. J Infect Dis. 2000;181(6):1875–84.
    1. Lessler J, et al. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291–300.
    1. Harris JM, 2nd, Gwaltney JM., Jr Incubation periods of experimental rhinovirus infection and illness. Clin Infect Dis. 1996;23(6):1287–90.
    1. Gwaltney JM, Jr, Hendley JO, Patrie JT. Symptom severity patterns in experimental common colds and their usefulness in timing onset of illness in natural colds. Clin Infect Dis. 2003;36(6):714–23.
    1. Iwane MK, Prill MM, Lu X, Miller EK, Edwards KM, Hall CB. Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis. 2011;204(11):1702–10.
    1. Singleton RJ, Bulkow LR, Miernyk K, DeByle C, Pruitt L, Hummel KB. Viral respiratory infections in hospitalized and community control children in Alaska. J Med Virol. 2010;82(7):1282–90.
    1. Graat JM, Schouten EG, Heijnen ML, Kok FJ, Pallast EG, de Greeff SC, et al. A prospective, community-based study on virologic assessment among elderly people with and without symptoms of acute respiratory infection. J Clin Epidemiol. 2003;56(12):1218–23.
    1. Armengol CE, Hendley JO, Winther B. Occurrence of acute otitis media during colds in children younger than four years. Pediatr Infect Dis J. 2011;30(6):518–20.
    1. Marom T, Nokso-Koivisto J, Chonmaitree T. Viral-bacterial interactions in acute otitis media. Curr Allergy Asthma Rep. 2000;12(6):551–8.
    1. Esposito S, Marchisio P, Tenconi R, Tagliaferri L, Albertario G, Patria MF, et al. Diagnosis of acute rhinosinusitis. Pediatr Allergy Immunol. 2012;23(22):17–9.
    1. Welge-Lussen A, Wolfensberger M. Olfactory disorders following upper respiratory tract infections. Adv Otorhinolaryngol. 2006;63:125–32.
    1. Papadopoulos NG. Do rhinoviruses cause pneumonia in children? Paediatr Respir Rev. 2004;5(A):S191–S195.
    1. Ruuskanen O, et al. Viral pneumonia. Lancet. 2011;377(9773):1264–75.
    1. Corne JM, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359(9309):831–4.
    1. Papadopoulos NG, et al. Viruses and bacteria in acute asthma exacerbations–a GA(2) LEN-DARE systematic review. Allergy. 2011;66(4):458–68.
    1. Wark PA, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med. 2005;201(6):937–47.
    1. Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, et al. Upper-respiratory viral infection, biomarkers, and COPD exacerbations. Chest. 2010;138(4):896–904.
    1. de Almeida MB, Zerbinati RM, Tateno AF, Oliveira CM, Romão RM, Rodrigues JC, et al. Rhinovirus C and respiratory exacerbations in children with cystic fibrosis. Emerg Infect Dis. 2010;16(6):996–9.
    1. Crooks BN, Taylor CE, Turner AJ, Osman HK, Abinun M, Flood TJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant. 2000;26(10):1097–102.
    1. Kraft CS, Jacob JT, Sears MH, Burd EM, Caliendo AM, Marshall Lyon G. Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza. J Clin Microbiol. 2012;50(3):1061–3.
    1. Luinstra K, Petrich A, Castriciano S, Ackerman M, Chong S, Carruthers S, et al. Evaluation and clinical validation of an alcohol-based transport medium for preservation and inactivation of respiratory viruses. J Clin Microbiol. 2011;49(6):2138–42.
    1. Landry ML, Cohen S, Ferguson D. Impact of sample type on rapid detection of influenza virus A by cytospin-enhanced immunofluorescence and membrane enzyme-linked immunosorbent assay. J Clin Microbiol. 2000;38(1):429–30.
    1. Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Söderlund-Venermo M. Human bocavirus-the first 5 years. Rev Med Virol. 2012;22(1):46–64.
    1. Mahony JB, Petrich A, Smieja M. Molecular diagnosis of respiratory virus infections. Crit Rev Clin Lab Sci. 2011;48(5–6):217–49.
    1. Jartti T, Söderlund-Venermo M, Hedman K, Ruuskanen O, Mäkelä MJ. New molecular virus detection methods and their clinical value in lower respiratory tract infections in children. Paediatr Respir Rev. 2013;14(1):38–45.
    1. Turner RB, Fuls JL, Rodgers ND, Goldfarb HB, Lockhart LK, Aust LB. A randomized trial of the efficacy of hand disinfection for prevention of rhinovirus infection. Clin Infect Dis. 2012;54(10):1422–6.
    1. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52(1):1–7.
    1. Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, et al. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. Vaccine. 2013;31(48):5706–12.
    1. Simancas-Racines D, Guerra CV, Hidalgo R. Vaccines for the common cold. Cochrane Database Syst Rev. 2013;6:CD002190.
    1. Fu YH, He JS, Qiao W, Jiao YY, Hua Y, Zhang Y, et al. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice. Virol J. 2013;10:183.
    1. Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One. 2012;7(5):e36812.
    1. Rigter A, Widjaja I, Versantvoort H, Coenjaerts FEJ, van Roosmalen M, Leenhouts K, et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One. 2013;8(8):e71072.
    1. Palmenberg AC, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science. 2009;324(5923):55–9.
    1. Bochkov YA, Palmenberg AC, Lee WM, Rathe JA, Amineva SP, Sun X, et al. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat Med. 2011;17(5):627–32.
    1. Megremis S, Demetriou P, Makrinioti H, Manoussaki AE, Papadopoulos NG. The genomic signature of human rhinoviruses A, B and C. PLoS One. 2012;7(9):e44557.
    1. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199–204.
    1. Niespodziana K, Napora K, Cabauatan C, Focke-Tejkl M, Keller W, Niederberger V, et al. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections. FASEB J. 2012;26(3):1001–8.
    1. Katpally U, Fu T-M, Freed DC, Casimiro DR, Smith TJ, et al. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol. 2009;83(14):7040–8.
    1. McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, et al. Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1. Antiviral Res. 2012;95(3):193–201.
    1. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602.
    1. Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther. 2011;28(2):91–109.
    1. Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011;204(11):1692–701.
    1. Clementi N, De Marco D, Mancini N, Solforosi L, Moreno GJ, Gubareva LV, et al. A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One. 2011;6(12):e28001.
    1. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–6.
    1. Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Non-steroidal anti-inflammatory drugs for the common cold. Cochrane Database Syst Rev. 2013;6:CD006362.
    1. Li S, et al. Acetaminophen (paracetamol) for the common cold in adults. Cochrane Database Syst Rev. 2013;7:CD008800.
    1. Simons FE. H1-antihistamines in children. Clin Allergy Immunol. 2002;17:437–64.
    1. De Sutter AI, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database Syst Rev. 2012;2:CD004976.
    1. Meltzer EO, Caballero F, Scadding G. Treatment of congestion in upper respiratory diseases. Int J Gen Med. 2010;3:69–91.
    1. Fiebich BL, Collado JA, Stratz C, Valina C, Hochholzer W, Muñoz E, et al. Pseudoephedrine inhibits T-cell activation by targeting NF-kappaB, NFAT and AP-1 signaling pathways. Immunopharmacol Immunotoxicol. 2012;34(1):98–106.
    1. Albalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. Cochrane Database Syst Rev. 2013;6:CD008231.
    1. Singh M. Heated, humidified air for the common cold. Cochrane Database Syst Rev. 2013;6:CD001728.
    1. Baartmans M, et al. Steam inhalation therapy: severe scalds as an adverse side effect. Br J Gen Pract. 2012;62(600):e473–7.
    1. Dicpinigaitis PV. Cough: an unmet clinical need. Br J Pharmacol. 2011;163(1):116–24.
    1. Sen EF, Verhamme KM, Felisi M, 't Jong GW, Giaquinto C, Picelli G, et al. Effects of safety warnings on prescription rates of cough and cold medicines in children below 2 years of age. Br J Clin Pharmacol. 2011;71(6):943–50.
    1. Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, Heneghan CJ. Corticosteroids for the common cold. Cochrane Database Syst Rev. 2012;8:CD008116.
    1. Barrett B, et al. Echinacea for treating the common cold: a randomized trial. Ann Intern Med. 2010;153(12):769–77.
    1. Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. 2013;6:CD001364.
    1. Mao S, Huang S. Vitamin D supplementation and risk of respiratory tract infections: a meta-analysis of randomized controlled trials. Scand J Infect Dis. 2013;45(9):696–702.
    1. Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol. 2013;136:321–9.
    1. Bergman P, Lindh AU, Björkhem-Bergman L, Lindh JD, et al. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(6):e65835.
    1. Science M, Maguire JL, Russell ML, Smieja M, Walter SD, Loeb M. Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents. Clin Infect Dis. 2013;57(3):392–7.
    1. Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308(13):1333–9.
    1. Arroll B. Common cold. Am Fam Physician. 2011;84(12):1390–1.
    1. Maggini S, Beveridge S, Suter M. A combination of high-dose vitamin C plus zinc for the common cold. J Int Med Res. 2012;40(1):28–42.
    1. Hemila H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;1:CD000980.
    1. Linde K, Barrett B, Wölkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006;1:CD000530.
    1. Nahas R, Balla A. Complementary and alternative medicine for prevention and treatment of the common cold. Can Fam Physician. 2011;57(1):31–6.
    1. Jawad M, et al. Safety and efficacy profile of echinacea purpurea to prevent common cold episodes: a randomized, double-blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2012;2012:841315.
    1. Kang EJ, Kim SY, Hwang IH, Ji YJ. The effect of probiotics on prevention of common cold: a meta-analysis of randomized controlled trial studies. Korean J Fam Med. 2013;34(1):2–10.
    1. Hao Q, Lu Z, Dong BR, Huang CQ, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9:CD006895.
    1. Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682–7.
    1. Shinkai S, Toba M, Saito T, Sato I, Tsubouchi M, Taira K, et al. Immunoprotective effects of oral intake of heat-killed Lactobacillus pentosus strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2013;109(10):1856–65.
    1. Marotta F, et al. Is there a potential application of a fermented nutraceutical in acute respiratory illnesses? An in-vivo placebo-controlled, cross-over clinical study in different age groups of healthy subjects. J Biol Regul Homeost Agents. 2012;26(2):285–94.
    1. Ganesan S, Faris AN, Wang Q, Nanua S, Hershenson MB, et al. Quercetin inhibits rhinovirus replication in vitro and in vivo. Antiviral Res. 2012;94(3):258–71.
    1. Song JH, Park KS, Kwon DH, Choi HJ. Anti-human rhinovirus 2 activity and mode of action of quercetin-7-glucoside from Lagerstroemia speciosa. J Med Food. 2013;16(4):274–9.
    1. Heinz SA, Henson DA, Austin MD, Jin F, Nieman DC. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. Pharmacol Res. 2010;62(3):237–42.
    1. Riede L, Grube B, Gruenwald J. Larch arabinogalactan effects on reducing incidence of upper respiratory infections. Curr Med Res Opin. 2013;29(3):251–8.
    1. Leibbrandt A, Meier C, König-Schuster M, Weinmüllner R, Kalthoff D, Pflugfelder B, et al. Iota-carrageenan is a potent inhibitor of influenza A virus infection. PLoS One. 2010;5(12):e14320.
    1. Grassauer A, Meier C, Pretsch A, Prieschl-Grassauer E, Unger H. Iota-carrageenan is a potent inhibitor of rhinovirus infection. Virol J. 2008;5:107.
    1. Eccles R, Meier C, Prieschl-Grassauer E. Efficacy and safety of an antiviral iota-carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res. 2010;11:108.
    1. Fazekas T, Eickhoff P, Pruckner N, Vollnhofer G, Fischmeister G, Diakos C, et al. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complement Altern Med. 2012;12:147.
    1. Auinger A, Riede L, Bothe G, Busch R, Gruenwald J. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. Eur J Nutr. 2013;52(8):1913–8.
    1. Graubaum H-J, Busch R, Stier H, Gruenwald J. A doubleblind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system. Food Nut Sci. 2012;3:738–746.
    1. Yates PJ, et al. Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrob Agents Chemother. 2013;57(4):1677–84.
    1. Michiels B, et al. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348.
    1. Wang K, et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only) Cochrane Database Syst Rev. 2012;4:CD002744.
    1. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010;23(1):74–98.
    1. Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. 2011;38(2):401–8.
    1. Sun Z, et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Virus. 2013;5(1):211–25.
    1. Maugeri C, et al. New anti-viral drugs for the treatment of the common cold. Bioorg Med Chem. 2008;16(6):3091–107.
    1. Patick AK. Rhinovirus chemotherapy. Antiviral Res. 2006;71(2–3):391–6.
    1. Rollinger JM, Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev. 2011;31(1):42–92.
    1. Gwaltney JM, Jr, et al. Combined antiviral-antimediator treatment for the common cold. J Infect Dis. 2002;186(2):147–54.
    1. Gao L, et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010;28(28):4445–51.
    1. Campbell-Harding G, Sawkins H, Bedke N, Holgate ST, Davies DE, Andrews AL, et al. The innate antiviral response upregulates IL-13 receptor alpha2 in bronchial fibroblasts. J Allergy Clin Immunol. 2013;131(3):849–55.
    1. Yamaya M, et al. Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Antimicrob Agents Chemother. 2012;56(8):4052–61.
    1. Koutsoubari I, et al. Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study. Pediatr Allergy Immunol. 2012;23(4):385–90.
    1. Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012;2012:649570.
    1. Jurgeit A, et al. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog. 2012;8(10):e1002976.
    1. Yoshihara S, et al. Inhibition of common cold-induced aggravation of childhood asthma by leukotriene receptor antagonists. Allergol Int. 2012;61(3):405–10.
    1. Kozer E, et al. RCT of montelukast as prophylaxis for upper respiratory tract infections in children. Pediatrics. 2012;129(2):e285–90.
    1. Kloepfer KM. Effects of montelukast on patients with asthma after experimental inoculation with human rhinovirus 16. Ann Allergy Asthma Immunol. 2011;106(3):252–7.
    1. Yamaya M, et al. Inhibitory effects of tiotropium on rhinovirus infection in human airway epithelial cells. Eur Respir J. 2012;40(1):122–32.
    1. Gern JE, et al. Inhibition of rhinovirus replication in vitro and in vivo by acid-buffered saline. J Infect Dis. 2007;195(8):1137–43.
    1. Van Blerkom LM. Role of viruses in human evolution. Am J Phys Anthropol. 2003;37:14–46.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe